In a multi-institution study of 298 invasive breast carcinomas, concordance between HER2 gene amplification by SISH and FISH was 96.6% when analyzed by FDA approved criteria and 98.9% when analyzed by ASCO/CAP guidelines after excluding equivocal cases [197]. This evidence concerns the gene ERBB2 and invasive breast carcinoma.